Immunocore (IMCR) Q4 2025 earnings review
KIMMTRAK Reaches $400M, But R&D Ramp Pushes Bottom Line Deeper Into the Red
Immunocore capped FY25 with its 15th consecutive quarter of KIMMTRAK revenue growth, bringing Q4 sales to $104.5M (+24% YoY) and full-year sales to $400.0M. However, the commercial success is being entirely consumed by an accelerating clinical investment cycle. Net Loss reversed from near-breakeven earlier in the year to a steep -$30.1M in Q4, driven by a 29% YoY spike in R&D expenses to support three Phase 3 trials and an imminent leap into autoimmune diseases. With management explicitly guiding for 'moderating' KIMMTRAK growth in 2026, the company's valuation relies heavily on clinical execution rather than near-term profitability.
🐂 Bull Case
KIMMTRAK's real-world mean duration of treatment in the US has extended to 14 months, significantly outperforming initial clinical trial data and acting as a powerful compounding tailwind for revenue.
Ending the year with $864.2M in cash and marketable securities provides Immunocore with massive financial flexibility. They can fully fund their three pivotal Phase 3 trials (TEBE-AM, ATOM, PRISM-MEL-301) through data readouts without near-term dilutive risk.
🐻 Bear Case
Despite a strong +24% YoY print, sequential revenue growth practically stalled in Q4 ($104.5M vs $103.7M in Q3). With management calling for moderating growth in 2026, the current mUM market is approaching saturation.
Any hopes of near-term breakeven have vanished. R&D spending accelerated to nearly $80M in Q4, and will likely remain elevated as the company advances multiple late-stage oncology trials alongside new autoimmune clinical entries.
⚖️ Verdict: ⚪
Neutral. The commercial execution of KIMMTRAK remains flawless, but the transition from a single-product growth story to a broad pipeline developer brings heavy costs. Investors must weather moderating revenue growth while waiting for the H2 2026 Phase 3 TEBE-AM and PRAME data readouts.
Key Themes
European Market Penetration Accelerating
While US growth is settling into the low teens (+13% YoY), Europe remains an aggressive growth engine. European Q4 sales surged 79% YoY to $32.1M, driven by recent successful launches and established pricing reimbursements across major markets like the UK, Poland, and the Netherlands.
Therapy Duration Extending Beyond Trial Metrics
The primary driver keeping US revenues growing is the increasing duration of therapy (DoT). Real-world DoT has stretched to 14 months. Oncologists are keeping patients on KIMMTRAK beyond initial progression due to its manageable safety profile and sustained quality-of-life benefits.
Sequential Revenue Stagnation Contradicts YoY Narrative
While the headline boasts 24% YoY growth, a closer look at the sequential data reveals a concerning plateau. Q4 revenue of $104.5M was a negligible increase over Q3's $103.7M (+0.7%). This specific data point confirms that KIMMTRAK's core market penetration is maturing rapidly, forcing reliance on future label expansions (TEBE-AM) for the next leg of growth.
Accelerating R&D Spend Pressures Bottom Line
R&D expense accelerated sharply to $78.8M in Q4, up from $60.9M a year ago. Management attributed this to clinical material manufacturing for autoimmune programs and Phase 3 trial progression. This structural shift in spending definitively delays any prior expectations of near-term corporate profitability.
TEBE-AM Control Arm Scrutiny
The Phase 3 TEBE-AM trial for second-line cutaneous melanoma remains the company's most critical mid-term catalyst. However, investors have consistently raised concerns regarding FDA scrutiny over oncology trial designs, specifically whether Immunocore can adequately prove KIMMTRAK's contribution to overall survival if the monotherapy arm fails against the investigator's choice control.
ImmTAAI Autoimmune Platform Moving to Clinic
Immunocore is officially expanding beyond oncology and infectious diseases. The company filed a Clinical Trial Application for IMC-S118AI (PPI x PD1), designed for tissue-specific down-modulation in Type 1 Diabetes, and will initiate Phase 1 in 1H 2026. This fundamentally expands the total addressable market of the company's bispecific TCR technology platform.
Rigorous SG&A Discipline
Despite massive R&D inflation and ongoing global commercial expansions, management held Q4 SG&A expenses remarkably flat at $42.6M (vs $42.3M in 24Q4). This demonstrates excellent operational leverage on the commercial side, ensuring that cash burn is entirely concentrated on value-creating clinical assets.
Other KPIs
Stable. The company added $43.8M to its war chest compared to the end of 2024 ($820.4M), benefiting from robust interest income ($16.5M for FY25) and disciplined working capital management, which helps buffer the increasing operating losses from the pipeline expansion.
Reversing. While the full-year loss improved versus FY24 (-$51.1M), the intra-year trajectory was negative. The company posted a $5.0M profit in Q1, which eroded into a $30.1M loss by Q4 as Phase 3 clinical trial expenses ramped up.
Guidance
Decelerating. Management explicitly stated that revenue growth will moderate in 2026. Given the sequential flattening observed in Q4 ($104.5M vs Q3's $103.7M), growth rates will likely compress into the single digits as the drug enters its fifth year on the market.
Stable. The company remains on track to complete enrollment for this pivotal Phase 3 cutaneous melanoma trial in 1H 2026, with overall survival (OS) event-driven topline data expected as early as the second half of 2026.
Stable. Data presentations for brenetafusp in ovarian and non-small cell lung cancer, alongside initial data for the half-life extended candidate (IMC-P115C), are locked in for the back half of the year.
Key Questions
Defining 'Moderating' Growth
With Q4 sequential growth essentially flat at under 1%, does 'moderating growth in 2026' imply low-single-digit YoY expansion, or should we model for a true plateau until label expansions occur?
R&D Baseline Spending
R&D spiked to nearly $79 million in Q4. Given the activation of the autoimmune clinical trials alongside three ongoing Phase 3 oncology studies, should investors view Q4 as the new quarterly floor for R&D run-rates?
European Pricing and Rebates
The company previously mentioned a ~$65 million European rebate accrual payout. Has this cash outflow fully materialized in Q4, and how will established pricing agreements in France and Germany impact 2026 net margins?
TEBE-AM Control Arm Assumptions
In the TEBE-AM trial, how is management adjusting statistical powering assumptions considering the rapidly evolving real-world treatment paradigms and off-label usage in 2L+ cutaneous melanoma?